A pneumococcal protein that elicits interleukin-8 from pulmonary epithelial cells

Journal of Infectious Diseases

Volumn 181, Issue 4, 2000, Pages 1330-1336

  Madsen, Melanie ^a,c   Lebenthal, Yael ^b,d   Cheng, Qi ^a,e   Smith, Beverly L ^a   Hostetter, Margaret K ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CELL PROTEIN; INTERLEUKIN 1; INTERLEUKIN 8;

ARTICLE; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LEUKOCYTOSIS; LOBAR PNEUMONIA; LUNG ALVEOLUS CELL TYPE 2; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; STREPTOCOCCUS PNEUMONIAE;

BACTERIAL PROTEINS; CARRIER PROTEINS; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-8; LUNG; MOLECULAR WEIGHT; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0034021077     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315388     Document Type: Article

References (42)

1. 1. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280-4.
2. 2. Johnston RB. Pathogenesis of pneumococcal pneumonia. Rev Infect Dis 1991; 13:S509-17.
3. 3. Toews GB, Vial WC. The role of C5 in polymorphonuclear leukocyte recruitment in response to Streptococcus pneumoniae. Am Rev Respir Dis 1984; 129:82-6.
4. 4. Fine DP. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun 1975; 12:772-8.
5. 5. Ward HK, Enders JF. An analysis of the opsonic and tropic action of normal and immune sera based on experiments with pneumococcus. J Exp Med 1933; 57:527-47.
6. 6. Baggiolini M, Walz A, Kunkel SL. Neutrophil activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045-9.
7. 7. Standiford TJ, Kunkel SL, Basha MA, et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest 1990; 86:1945-53.
8. 8. Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989; 1:2-3.
9. 9. Kwon OJ, Au BT, Collins PD, et al. Tumor necrosis factor induced interleukin-8 expression in cultured human airway epithelial cells. Am J Physiol 1994; 267:L398-L405.
10. 10. Arnold R, Humbert B, Werchau H, Gallati H, Konig W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology 1994; 82:126-33.
11. 11. Fiedler MA, Wernke-Dollries K, Stark JM. Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. Am J Physiol 1995; 269:L865-72.
12. 12. Keicho N, Elliott WM, Hogg JC, Hayashi S. Adenovirus E1A upregulates interleukin-8 expression induced by endotoxin in pulmonary epithelial cells. Am J Physiol 1997; 272:L1046-52.
13. 13. Amin R, Wilmott R, Schwarz Y, Trapnell B, Stark J. Replication-deficient adenovirus induces expression of interleukin-8 by airway epithelial cells in vitro. Hum Gene Ther 1995; 6:145-53.
14. 14. Rosenthal GJ, Germolec DR, Blazka ME, et al. Asbestos stimulates IL-8 production from human lung epithelial cells. J Immunol 1994; 153: 3237-44.
15. 15. Tack BF, Janatova J, Thomas ML, Harrison RA, Hammer CH. Third, fourth, and fifth components of human complement: isolation and biochemical properties. Methods Enzymol 1982; 80:64-101.
16. 16. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989; 57:2037-42.
17. 17. Geelen S, Bhattacharyya C, Tuomanen E. The cell wall mediates pneumococcal attachment to and cytopathology in human endothelial cells. Infect Immun 1993; 61:1538-43.
18. 18. Lieber M, Smith BT, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976; 17:62-70.
19. 19. Smith BT. Cell line A549: a model system for the study of alveolar type II cell function. Am Rev Respir Dis 1977; 115:285-93.
20. 20. Cheng Q, Finkel D, Hostetter MK. Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry (in press).
21. 21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
22. 22. Macrina FL, Evans RP, Tobian JA, Hartley DL, Clewell DB, Jones KR. Novel shuttle plasmid vehicles for Escherichia-Streptococcus transgeneric cloning. Gene 1983; 25:145-50.
23. 23. Haverstein LS, Coomaraswamy G, Morrison DA. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc Natl Acad Sci USA 1995; 92:11140-4.
24. 24. Smith BL. Characterization of a pneumococcal surface protein which binds complement protein C3 and its role in adhesion [thesis]. Minneapolis: University of Minnesota, 1998.
25. 25. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4.
26. 26. Boulnois GJ, Paton JC, Mitchell TJ, Andrew PW. Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol Microbiol 1991; 5:2611-6.
27. 27. Hostetter MK, Krueger RA, Schmeling DJ. The biochemistry of opsonization: central role of the reactive thiolester of the third component of complement. J Infect Dis 1984; 150:653-62.
28. 28. Alper CA, Abramson N, Johnston RB, Jandl JH, Rosen FS. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med 1970; 282:350-54.
29. 29. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984; 63:243-73.
30. 30. Shin HS, Smith MR, Wood WB Jr. Heat-labile opsonins to pneumococcus. II. Participation of C3 and C5. J Exp Med 1969; 130:1229-40.
31. 31. Johnston RB Jr, Klemperer MR, Alper CA, Rosen FS. The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med 1969; 129:1275-90.
32. 32. Winkelstein JA, Abramovitz AS, Tomasz A. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol 1980; 124:2502-6.
33. 33. Brown EJ, Joiner KA, Gaither TA, Hammer CU, Frank MM. The interaction of C3b bound to pneumococci with factor H (β1H globulin), factor I (C3b/C4b inactivator) and properdin factor B of the human complement system. J Immunol 1983; 131:409-15.
34. 34. Paton JC, Rowan-Kelley B, Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 1984; 43:1085-7.
35. 35. Hostetter MK. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b. Implications for phagocytosis and antibody production. J Infect Dis 1986; 153:682-93.
36. 36. Neeleman C, Geelen SPM, Aerts PC, et al. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun 1999; 67:4517-24.
37. 37. Tu AMT, Fulgham RL, McCrory MA, Briles DA, Szalai AJ. Pneumcococal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 1999; 67:4720-4.
38. 38. Cole FS, Matthews WJ, Rossing TH, Gash DJ, Lichtenberg NA, Pennington JE. Complement biosynthesis by human bronchoalveolar macrophages. Clin Immunol Immunopathol 1983; 27:153-9.
39. 39. Rothman BL, Merrow M, Bamba M, Kennedy T, Kreutzer DL. Biosynthesis of the third and fifth complement components by isolated human lung cells. Am Rev Respir Dis 1989; 139:212-20.
40. 40. Strunk RC, Eidlen DM, Mason RJ. Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988; 81:1419-26.
41. 41. Rosenow C, Ryan P, Weiser JN, et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997; 25:819-29.
42. 42. Hammerschmidt S, Talay SR, Brandtzaeg P, Chhatwal GS. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 1997; 25:1113-24.